ArticleInternational journal of clinical and experimental pathology2026
Fascin-1 expression in advanced colorectal cancer is associated with the treatment efficacy of cetuximab.
Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAlthough several studies have reported that Fascin-1 is upregulated in colorectal cancer and promotes tumor progression, its relationship with therapeutic efficacy in patients with colorectal cancer remains unclear. This study aimed to investigate the effect of Fascin-1 protein expression on the efficacy of cetuximab treatment in patients with advanced colorectal cancer (CRC).
methodsImmunohistochemical (IHC) staining was used to evaluate the protein expression of Fascin-1 in tissues from 40 patients with advanced CRC. The RECIST criteria were applied to evaluate the efficacy of cetuximab-targeted therapy in CRC patients.
resultsAmong the 40 advanced CRC patients treated with cetuximab, 12 (30%, 12/40) achieved an objective response, and 28 (70%, 28/40) achieved disease control. IHC results revealed that 18 out of 40 CRC tissues (45%, 18/40) were positive for the Fascin-1 protein. Analysis of the relationship between Fascin-1 expression and treatment efficacy revealed that the objective response rate (ORR) in Fascin-1-positive CRC patients was 11.1% (2/18), which was significantly lower than that in Fascin-1-negative patients (45.5%, 10/22) (
conclusionsFascin-1 expression status is significantly correlated with the efficacy of cetuximab treatment. Combined intervention against Fascin-1 may be an effective strategy for improving the outcome of patients with RAS wild-type advanced CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.